Guardant Health, Inc. (GH)

Over the past six months, Guardant Health's stock has experienced several notable events. In January 2026, the company announced preliminary unaudited results for Q4 and full year 2025, reporting revenue increases. In February 2026, Guardant Health reported Q4 2025 earnings, missing EPS estimates but beating revenue expectations. In April 2026, the stock slid after FDA briefing documents raised concerns about AstraZeneca's SERENA-6 trial, Guardant Health announced a collaboration with Nuvalent, and the company disclosed the resignation of Chief Medical Officer Craig Eagle. In May 2026, Guardant Health surged after receiving FDA approval for Guardant360 CDx, reported Q1 2026 financial results with revenue increasing, and raised its full-year 2026 revenue guidance. Guardant Health's stock price has ranged between a low of $36.36 and a high of $120.74 over the past 52 weeks.

While specific detailed information on demand seasonality for Guardant Health's products and services is not extensively available, an analysis of its seasonal stock chart suggests a period of seasonal strength for the Healthcare sector, which runs from approximately April 25 to December 4. A "Buy Date" of May 9 and a "Sell Date" of September 15 has historically resulted in a geometric average return of 17.97% above the S&P 500 Total Return Index over the past 7 years. This indicates a potential seasonal pattern in investor interest and stock performance. The company's revenue is generated from test fees, which could be influenced by factors such as patient diagnoses, treatment cycles, and healthcare spending patterns throughout the year.

Guardant Health, Inc. is a precision oncology company specializing in liquid-based cancer tests for clinical and research use. The company operates within the Healthcare sector, specifically in the Diagnostics & Research industry. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners, and researchers worldwide through proprietary blood tests, vast datasets, and advanced analytics. Its major products and services include Guardant360, Guardant Reveal, Shield, GuardantOMNI, GuardantINFORM, LUNAR-2, GuardantConnect, Smart Platform, Development Services, and Guardant-19.

Guardant Health has a global presence, partnering with laboratories and cancer centers worldwide to expand access to its liquid biopsy tests. The company has expanded its service offerings across Europe and Asia through partnerships and regional laboratory certifications. It has offices in Singapore, Japan, China, and India, and is committed to expanding access to its tests across Europe and Canada. Guardant Health also licenses cancer tests to clinical laboratory companies for research testing in China.

Guardant Health is recognized as a leader in liquid-based cancer tests and precision oncology. Its brand reputation has been influenced by FDA approvals, strategic collaborations, revenue growth, legal matters, and product performance. Multiple FDA approvals for Guardant360 CDx and Shield have reinforced its leadership. Strategic collaborations enhance its reputation for innovation. Consistently reporting strong revenue growth contributes positively to its reputation. Legal battles and a civil investigative demand introduce regulatory and financial risk. Early results for the Shield test caused a stock price drop and some negative sentiment.

Guardant Health, Inc. stock ownership is a mix of institutional, insider, and retail investors. As of May 6, 2026, Guardant Health has 506 institutional owners holding a total of 128,922,361 shares. Softbank Vision Fund Aiv M1 LP is the largest individual Guardant Health shareholder, owning 25.82 million shares, representing 19.68% of the company. Insiders collectively own approximately 3.62% of the company's stock.